Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Operating Expenses: 2019-2024

Historic Operating Expenses for Compass Therapeutics (CMPX) over the last 6 years, with Dec 2024 value amounting to $57.5 million.

  • Compass Therapeutics' Operating Expenses rose 29.23% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.4 million, marking a year-over-year increase of 26.87%. This contributed to the annual value of $57.5 million for FY2024, which is 14.12% up from last year.
  • Compass Therapeutics' Operating Expenses amounted to $57.5 million in FY2024, which was up 14.12% from $50.4 million recorded in FY2023.
  • In the past 5 years, Compass Therapeutics' Operating Expenses ranged from a high of $81.9 million in FY2021 and a low of $32,105 during FY2020.
  • For the 3-year period, Compass Therapeutics' Operating Expenses averaged around $49.8 million, with its median value being $50.4 million (2023).
  • Per our database at Business Quant, Compass Therapeutics' Operating Expenses surged by 194.41% in 2021 and then plummeted by 49.13% in 2022.
  • Over the past 5 years, Compass Therapeutics' Operating Expenses (Yearly) stood at $32,105 in 2020, then decreased by 18.32% to $27.8 million in 2020, then surged by 194.41% to $81.9 million in 2021, then slumped by 49.13% to $41.7 million in 2022, then increased by 20.91% to $50.4 million in 2023, then climbed by 14.12% to $57.5 million in 2024.